
    
      Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell
      lymphoma in China (Chidamide,a novel histone deacetylase inhibitor). Tirelizumab,has been
      approved for the failure treatment of platinum-containing chemotherapy with high PD-L1
      expression included locally advanced or metastatic Urothelial carcinoma in
      China(Tirelizumab,BGB-A317 is an investigational humanized IgG4 anti-PD-1 monoclonal antibody
      ).The aim of this study was to observe the efficacy and safety of Chidamide with
      Immunotherapy in patients with progression of platinum-based chemotherapy recurrent and
      metastatic Urothelial carcinoma.
    
  